An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
At a glance
- Drugs GDC 0425 (Primary) ; Gemcitabine
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 04 Nov 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 09 Jun 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 12 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 May 2014.